Serious medical comorbidities generally preclude curative therapies for patients with leukemia. Arsenic trioxide (As2O3), both intravenous and oral, is highly effective for acute promyelocytic leukemia (APL).1 As arsenic is eliminated mainly by renal excretion, uremic patients are considered unsuitable for arsenic trioxide therapy. To our knowledge, there are no data on arsenic clearance during dialysis. A patient with APL who was receiving continuous ambulatory peritoneal dialysis (CAPD) was successfully treated with oral arsenic trioxide. We took this unique opportunity to study arsenic clearance during CAPD.
Au W, Cheung GT, Yuen TW, Kumana CR, Kwong Y. Successful Treatment of Relapsed Acute Promyelocytic Leukemia in a Patient Receiving Continuous Ambulatory Peritoneal Dialysis With Oral Arsenic Trioxide. Arch Intern Med. 2005;165(9):1067–1068. doi:10.1001/archinte.165.9.1067
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.